Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery
Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery
Background:

 1. . The incidence and mortality of colon cancer are high in China and in the world.

 2. . The treatment of many patients in the real world is not standardized, and there are
 problems such as over-treatment or under-treatment. To explore the adjuvant treatment of
 colon cancer in the Chinese population, this study will retrospectively analyze
 real-world data on adjuvant therapy for colon cancer in Chinese patients after radical
 surgery.

 The purpose of research:

 1. . Current status of adjuvant therapy for stage II-III colon cancer in the real world:
 chemotherapy regimen, chemotherapy time, efficacy, safety, etc.

 2. . Comparison of efficacy and safety of different adjuvant chemotherapy time (<3 months
 vs. >=3 months) in high-risk stage II and III colon cancer patients in the real world

 3. . Comparison of efficacy and safety of different adjuvant chemotherapy regimens (XELOX
 vs. FOLFOX) in high-risk stage II and III colon cancer patients in the real world
Inclusion Criteria:

 -  Patients who are sick after January 2010

 -  Age is older than 18

 -  Surgical pathology confirmed TNM stage II-III (AJCC 7th edition) colon cancer

 Exclusion Criteria:

 -  Combine other tumors

 -  Pathological information is not clear

 -  Researchers believe that other reasons are not suitable for enrollment